T cell immune abnormalities in immune thrombocytopenia

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Ji, Xuebin ^a   Zhang, Liping ^b   Peng, Jun ^a   Hou, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINAN STOMATOLOGICAL HOSPITAL   (China)

Author keywords

Immune thrombocytopenia; Immune tolerance; Pathogenesis; T cell

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UBIQUITIN;

AUTOIMMUNE DISEASE; CELL MATURATION; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE THROMBOCYTOPENIA; MEGAKARYOCYTE; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T CELL IMMUNE ABNORMALITY; TH1 TH2 BALANCE; THROMBOCYTOPENIA; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; THROMBOCYTOPENIA;

EID: 84908009137     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0072-6     Document Type: Review

References (58)

1. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. B Olsson, PO Andersson, S Jacobsson, L Carlsson, A Wadenvik, Thromb Haemost 2005 93 139 144 15630504
2. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. XL Zhang, J Peng, JZ Sun, CS Guo, Y Yu, ZG Wang, XX Chu, M Hou, J Thromb Haemost 2008 6 158 165 10.1111/j.1538-7836.2007.02804.x 17944988
3. De novo induction of platelet-specific CD4(+) CD25(+) regulatory T cells from CD4(+) CD25(-) cells in patients with idiopathic thrombocytopenic purpura. XL Zhang, J Peng, JZ Sun, JJ Liu, CS Guo, ZG Wang, Y Yu, Y Shi, P Qin, SG Li, LN Zhang, M Hou, Blood 2009 113 2568 2577 10.1182/blood-2008-03-148288 19056692
4. Thymic retention of CD4 + CD25 + FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. R Aslam, Y Hu, S Gebremeskel, GB Segel, ER Speck, L Guo, M Kim, H Ni, J Freedman, JW Semple, Blood 2012 120 2127 2132 10.1182/blood-2012-02-413526 22760780
5. In vitro recovery of Th1/Th2 balance in PBMCs from patients with immune thrombocytopenia through the actions of IL-18BPa/Fc. NN Shan, XB Ji, X Wang, Y Li, X Liu, XJ Zhu, M Hou, Thromb Res 2011 128 119 e124 10.1016/j.thromres.2011.07.012 21911248
6. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. T Wang, H Zhao, H Ren, J Guo, M Xu, R Yang, ZC Han, Haematologica 2005 90 914 923 15996929
7. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. S Li, L Wang, C Zhao, L Li, J Peng, M Hou, Br J Haematol 2007 139 605 611 10.1111/j.1365-2141.2007.06737.x 17979946
8. Contributions of TRAIL mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. L Yang, L Wang, CH Zhao, XJ Zhu, Y Hou, J Peng, M Hou, Blood 2010 116 4307 4316 10.1182/blood-2010-02-267435 20671119
9. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. J Peng, C Liu, D Liu, C Ren, W Li, Z Wang, N Xing, C Xu, X Chen, C Ji, M Zhang, M Hou, Blood 2003 101 2721 2726 10.1182/blood-2002-06-1666 12446456
10. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. JR Abrams, SL Kelley, E Hayes, T Kikuchi, MJ Brown, S Kang, MG Lebwohl, CA Guzzo, BV Jegasothy, PS Linsley, JG Krueger, J Exp Med 2000 192 681 694 10.1084/jem.192.5.681 10974034
11. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. K Kokame, M Matsumoto, K Soejima, H Yagi, H Ishizashi, M Funato, H Tamai, M Konno, K Kamide, Y Kawano, T Miyata, Y Fujimura, Proc Natl Acad Sci U S A 2002 99 11902 11907 10.1073/pnas.172277399 12181489
12. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. M Suzuki, M Murata, Y Matsubara, T Uchida, H Ishihara, T Shibano, S Ashida, K Soejima, Y Okada, Y Ikeda, Biochem Biophys Res Commun 2004 313 212 216 10.1016/j.bbrc.2003.11.111 14672719
13. Chemically dimerized intravenous immunoglobulin has potent amelioratingactivity in a mouse immune thrombocytopenic purpura model. Y Machino, E Suzuki, S Higurashi, H Ohta, M Suzuki, J Kohroki, Y Masuho, Biochem Biophys Res Commun 2012 418 748 753 10.1016/j.bbrc.2012.01.092 22306012
14. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment. OF Bathe, N Dalyot-Herman, TR Malek, BMC Cancer 2003 3 21 10.1186/1471-2407-3-21 12882650
15. Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities. Y Yao, L Chen, W Wei, X Deng, L Ma, S Hao, Biochem Biophys Res Commun 2013 436 60 65 10.1016/j.bbrc.2013.05.058 23707941
16. The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131. Y Choi, HW Lee, J Lee, YH Jeon, BMC Cancer 2013 13 143 10.1186/1471-2407-13-143 23522027
17. Leukotriene B4 augments human natural cytotoxic cell activity. M Rola-Pleszczynski, L Gagnon, P Sirois, Biochem Biophys Res Commun 1983 113 531 537 10.1016/0006-291X(83)91758-8 6307292
18. The role of CD4 T cell help for CD8 CTL activation. S Zhang, H Zhang, J Zhao, Biochem Biophys Res Commun 2009 384 405 408 10.1016/j.bbrc.2009.04.134 19410556
19. T cell precursor frequency differentially affects CTL responses under different immune conditions. Z Ye, KA Ahmed, J Huang, Y Xie, MA Munegowda, J Xiang, Biochem Biophys Res Commun 2008 367 427 434 10.1016/j.bbrc.2007.12.149 18178159
20. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. C Zhao, X Li, F Zhang, L Wang, J Peng, M Hou, Haematologica 2008 93 1428 1430 10.3324/haematol.12889. 18757854
21. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. F Zhang, X Chu, L Wang, Y Zhu, L Li, D Ma, J Peng, M Hou, Eur J Haematol 2006 76 427 431 10.1111/j.1600-0609.2005.00622.x 16480433
22. The different effects of indirubin on effector and CD4 + CD25+ regulatory T cells in mice: potential implication for the treatment of autoimmune diseases. A Zhang, Y Qu, B Zhang, L Zhang, C Zeng, J Peng, X Ji, M Hou, Y Zhao, J Mol Med 2007 85 1263 1270 10.1007/s00109-007-0235-9 17639287
23. SMAD regulatory networks construct a balanced immune system. N Malhotra, J Kang, Immunology 2013 139 1 10 10.1111/imm.12076 23347175
24. Toll-like receptors and innate immunity. H Kumar, T Kawai, S Akira, Biochem Biophys Res Commun 2009 388 621 625 10.1016/j.bbrc.2009.08.062 19686699
25. Diterpenes inhibit IL-12 production by DC and enhance Th2 cells polarization. M Takei, A Umeyama, S Arihara, Biochem Biophys Res Commun 2007 355 603 610 10.1016/j.bbrc.2007.01.157 17316566
26. STAT6 inhibits T-bet-independent Th1 cell differentiation. T Tamachi, H Takatori, M Fujiwara, K Hirose, Y Maezawa, S Kagami, A Suto, N Watanabe, I Iwamoto, H Nakajima, Biochem Biophys Res Commun 2009 382 751 755 10.1016/j.bbrc.2009.03.101 19324016
27. Notch ligand mRNA levels of human APCs predict Th1/Th2-promoting activities. M Wakui, K Nakano, S Matsushita, Biochem Biophys Res Commun 2007 358 596 601 10.1016/j.bbrc.2007.04.175 17499611
28. Correction of Th1-dominant cytokine profiles by highdose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. C Guo, X Chu, Y Shi, W He, L Li, L Wang, Y Wang, J Peng, M Hou, J Clin Immunol 2007 27 557 562 10.1007/s10875-007-9111-1 17619126
29. Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. NN Shan, XJ Zhu, J Peng, P Qin, XW Zhuang, HC Wang, M Hou, Br J Haematol 2009 144 755 761 10.1111/j.1365-2141.2008.07520.x 19077159
30. High dose Dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. NN Shan, XJ Zhu, Q Wang, CY Wang, P Qin, J Peng, M Hou, Haematologica 2009 94 1603 1607 10.3324/haematol.2009.007708 19797730
31. Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura. D Ma, J Dai, X Zhu, S Yan, P Zhao, J Zhang, Y Zhu, J Sun, J Peng, C Ji, M Hou, Ann Hematol 2010 89 155 161 10.1007/s00277-009-0790-y 19603167
32. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. J Zhang, D Ma, X Zhu, X Qu, C Ji, M Hou, Haematologica 2009 94 1326 1329 10.3324/haematol.2009.007823 19734430
33. Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. X Zhu, D Ma, J Zhang, J Peng, X Qu, C Ji, M Hou, J Clin Immunol 2010 30 253 259 10.1007/s10875-009-9353-1 19997967
34. The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia. AM Rocha, C Souza, GA Rocha, FF de Melo, NC Clementino, MC Marino, DM Queiroz, J Hematol Oncol 2013 12 28 10.1186/1756-8722-6-28
35. Decreased expression of interleukin-27 in immune thrombocytopenia. XG Liu, J Ren, Y Yu, L Sun, Y Shi, P Qin, L Yang, SH Ma, XY Dong, DX Ma, X Qu, CS Guo, CY Chen, M Hou, J Peng, Br J Haematol 2011 153 259 267 10.1111/j.1365-2141.2011.08614.x 21385171
36. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. D Ma, X Zhu, P Zhao, C Zhao, X Li, Y Zhu, L Li, J Sun, J Peng, C Ji, M Hou, Ann Hematol 2008 87 899 904 10.1007/s00277-008-0535-3 18600325
37. Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): potential effect on immune surveillance. M Kamachi, T Aramaki, S Tanimura, K Ichinose, K Fujikawa, N Iwamoto, A Yoshizaki, H Ida, A Kawakami, M Kohno, K Eguchi, Biochem Biophys Res Commun 2007 360 280 285 10.1016/j.bbrc.2007.06.046 17583676
38. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. SA Crist, BD Elzey, AT Ludwig, TS Griffith, JB Staack, SR Lentz, TL Ratliff, Exp Hematol 2004 32 1073 1081 10.1016/j.exphem.2004.07.022 15539085
39. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. MC Filion, AJ Bradley, DV Devine, F Décary, P Chartrand, Eur J Immunol 1995 25 3123 3127 10.1002/eji.1830251120 7489752
40. ICOS costimulates invariant NK T cell activation. H Kaneda, K Takeda, T Ota, Y Kaduka, H Akiba, Y Ikarashi, H Wakasugi, M Kronenberg, K Kinoshita, H Yagita, K Okumura, Biochem Biophys Res Commun 2005 327 201 207 10.1016/j.bbrc.2004.12.004 15629449
41. CD28 and ICOS: similar or separate costimulators of T cells? ME van Berkel, MA Oosterwegel, Immunol Lett 2006 105 115 122 10.1016/j.imlet.2006.02.007 16580736
42. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. N Okamoto, K Tezuka, M Kato, R Abe, T Tsuji, Biochem Biophys Res Commun 2003 310 691 702 10.1016/j.bbrc.2003.09.065 14550257
43. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. XJ Zhu, Y Shi, J Peng, CS Guo, NN Shan, P Qin, XB Ji, M Hou, Blood 2009 114 5362 5367 10.1182/blood-2009-05-217513 19794139
44. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. A Hutloff, AM Dittrich, KC Beier, B Eljaschewitsch, R Kraft, I Anagnostopoulos, RA Kroczek, Nature 1999 397 263 266 10.1038/16717 9930702
45. ICOS co-stimulatory receptor is essential for T-cell activation and function. C Dong, AE Juedes, UA Temann, S Shresta, JP Allison, NH Ruddle, RA Flavell, Nature 2001 409 97 101 10.1038/35051100 11343121
46. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. CJ Shen, YX Yang, EQ Han, N Cao, YF Wang, Y Wang, YY Zhao, LM Zhao, J Cui, P Gupta, AJ Wong, SY Han, J Hematol Oncol 2013 9 33 10.1186/1756-8722-6-33
47. Targeting T cell costimulation in autoimmune disease. RW Stuart, MK Racke, Expert Opin Ther Targets 2002 6 275 289 10.1517/14728222.6.3.275 12223069
48. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. AJ Coyle, S Lehar, C Lloyd, J Tian, T Delaney, S Manning, T Nguyen, T Burwell, H Schneider, JA Gonzalo, M Gosselin, LR Owen, CE Rudd, JC Gutierrez-Ramos, Immunity 2000 13 95 105 10.1016/S1074-7613(00)00011-X 10933398
49. The function of the proteasome system in MHC class I antigen processing. L Stoltze, AK Nussbaum, A Sijts, NP Emmerich, PM Kloetzel, H Schild, Immunol Today 2000 21 317 319 10.1016/S0167-5699(00)01665-0 10950502
50. Protein degradation and the generation of MHC class I-presented peptides. KL Rock, IA York, T Saric, AL Goldberg, Adv Immunol 2002 80 1 70 10.1016/S0065-2776(02)80012-8 12078479
51. NF-κB control of T cell development. S Gerondakis, TS Fulford, NL Messina, RJ Grumont, Nat Immunol 2014 15 15 25 10.1038/ni.2785 24352326
52. NF-κB family of transcription factors: biochemical players of CD28 co-stimulation. L Tuosto, Immunol Lett 2011 135 1 9 30 10.1016/j.imlet.2010.09.005 20863851
53. Regulation of NF-κB induction by TCR/CD28. J Cheng, A Montecalvo, LP Kane, Immunol Res 2011 50 113 117 10.1007/s12026-011-8216-z 21717079
54. The proteasome in health and disease. E Jankowska, J Stoj, P Karpowicz, PA Osmulski, M Gaczynska, Curr Pharm Des 2013 19 1010 1028 10.2174/1381612811319060004 23016682
55. Development of Proteasome Inhibitors as Therapeutic Drugs. ST Pellom Jr, A Shanker, J Clin Cell Immunol 2012 S5 5 23338480
56. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. Y Yuan, YM Liao, CT Hsueh, HR Mirshahidi, J Hematol Oncol 2011 20 16 10.1186/1756-8722-4-16
57. Proteasome inhibitors. Y Saeki, K Fukunaga, K Tanaka, Nihon Rinsho 2010 68 1818 1822 20954323
58. Targeted therapy in lymphoma. PB Johnston, R Yuan, F Cavalli, TE Witzig, J Hematol Oncol 2010 23 45 10.1186/1756-8722-3-45